Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACHV 
Achieve Life Sciences Inc (ACHV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACHV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.23% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 161.49M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 8 | Beta 1.31 | 52 Weeks Range 1.84 - 5.31 | Updated Date 08/29/2025 |
52 Weeks Range 1.84 - 5.31 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.37 | Actual -0.37 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -50.63% | Return on Equity (TTM) -120.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 116054698 | Price to Sales(TTM) - |
Enterprise Value 116054698 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 51105000 | Shares Floating 42333311 |
Shares Outstanding 51105000 | Shares Floating 42333311 | ||
Percent Insiders 3.55 | Percent Institutions 61.41 |
Upturn AI SWOT
Achieve Life Sciences Inc
Company Overview
History and Background
Achieve Life Sciences, Inc. (ACHV) is a pharmaceutical company dedicated to developing and commercializing cytisine for smoking cessation and nicotine dependence. Originally known as Marina Biotech, the company underwent a strategic shift to focus on addiction treatment. The company has obtained exclusive, worldwide rights to develop and commercialize cytisine.
Core Business Areas
- Smoking Cessation: Achieve Life Sciences' core business focuses on the development and commercialization of cytisine, a plant-based alkaloid with a history of use in Central and Eastern Europe, for smoking cessation. Achieve is currently pursuing regulatory approval for Cytisine in the United States.
Leadership and Structure
The leadership team includes John Bencich, CEO, and Rick Stewart, CFO. The company operates with a focus on clinical development and regulatory affairs, preparing for potential commercialization.
Top Products and Market Share
Key Offerings
- Cytisine (developmental stage): Cytisine is Achieve's lead product candidate for smoking cessation. It is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Cytisine has a long history of use in Central and Eastern Europe for smoking cessation. Market share is currently 0% in the US since it is still in development. Key competitors, if approved, will include Pfizer (Chantix/varenicline) and Johnson & Johnson (Nicorette, Nicoderm CQ).
Market Dynamics
Industry Overview
The smoking cessation market is substantial, driven by the high prevalence of smoking and the increasing awareness of its health risks. The market includes nicotine replacement therapies (NRTs), prescription medications, and behavioral support programs.
Positioning
Achieve Life Sciences is positioned to compete with established smoking cessation treatments by offering cytisine as a potentially more accessible and affordable option. Their competitive advantage lies in Cytisine's established safety and efficacy profile in other markets and its potential for broader availability.
Total Addressable Market (TAM)
The global smoking cessation market is expected to reach billions of dollars. Achieve aims to capture a significant portion of this market by offering a new treatment option, positioning them for growth relative to this TAM, pending regulatory approval.
Upturn SWOT Analysis
Strengths
- Cytisine's proven efficacy and safety in other markets
- Potential for cost-effectiveness compared to existing treatments
- Clear focus on smoking cessation
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product candidate
- Lack of current revenue stream
- Dependence on regulatory approval
- Limited commercialization experience in the US
Opportunities
- Expanding into new geographic markets
- Developing new formulations or delivery methods for cytisine
- Partnering with healthcare providers and insurers
- Increasing public awareness of cytisine's benefits
Threats
- Competition from established smoking cessation treatments
- Regulatory hurdles and delays
- Patent challenges
- Changes in smoking rates and cessation trends
Competitors and Market Share
Key Competitors
- PFE
- JNJ
Competitive Landscape
Achieve Life Sciences faces intense competition from established pharmaceutical companies with approved smoking cessation medications and nicotine replacement therapies. Achieve's success depends on demonstrating cytisine's superiority in terms of efficacy, safety, or cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's pre-revenue status. Growth is primarily measured by progress in clinical trials and regulatory filings.
Future Projections: Future growth is heavily dependent on obtaining regulatory approval for cytisine and successfully commercializing the product. Analyst estimates vary widely based on the likelihood of approval and market penetration.
Recent Initiatives: Recent initiatives include completing Phase 3 clinical trials, preparing for regulatory submissions, and exploring potential partnerships.
Summary
Achieve Life Sciences is a high-risk, high-reward company focused on developing and commercializing cytisine for smoking cessation. The company's success hinges on securing regulatory approval and effectively competing in the established smoking cessation market. Positive clinical trial results have boosted investor confidence, but regulatory and commercialization risks remain significant. Achieve needs to successfully navigate the regulatory pathway and build a robust commercial strategy to realize its full potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on your own research and due diligence. Market share figures are estimates and may not reflect actual results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Achieve Life Sciences Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1995-10-13 | CEO & Executive Director Dr. Richard A. B. Stewart | ||
Sector Healthcare | Industry Biotechnology | Full time employees 25 | |
Full time employees 25 | |||
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.